Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New MRI trick could spot breast cancer without extra gadgets

NCT ID NCT07608068

Diagnosis Sponsor: Yunnan Cancer Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new MRI technique called virtual MR elastography (vMRE) that uses standard scans to measure breast tissue stiffness, which can help tell benign from malignant lesions. Researchers will compare vMRE to the traditional MRE method in 238 women with suspicious breast findings. The goal is to see if vMRE can replace or supplement MRE, making diagnosis easier and more widely available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Virtual MR Elastography (vMRE) via diffusion-weighted MRI
What this could lead to
If successful, vMRE could provide a simpler, more accessible way to diagnose breast cancer using standard MRI, reducing the need for specialized scans.
What could go wrong
This is an early-stage diagnostic study, not a treatment trial. The new technique may not be as accurate as standard MRE, and results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 238 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years or older * Female patients with breast lesions BI-RADS category 4 and above on mammography or ultrasound * Breast MRE and vMRE examinations should be performed within 2 weeks prior to needle biopsy or surgery * Obtaining definitive pathology via needle biopsy or postoperatively Exclusion Criteria: * Pregnant and lactating women * Previous history of breast treatment (e.g., surgery, radiotherapy, chemotherapy, or targeted therapy, etc.) * Inability to cooperate for MRI examination, or presence of severe artifacts (e.g., motion artifacts, metal artifacts) in the imaging data that precludes parameter measurement. * The lesion cannot be clearly identified or delineated on MRE or vMRE images * Complicated by severe cardiac, hepatic, or renal diseases, coagulation disorders, or other malignancies.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast - female are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm female breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast - female Breast cancer

Contacts and locations

Locations

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.